New hope for advanced cancer patients: experimental drug ABX-001 enters human trials
NCT ID NCT07231458
First seen Nov 17, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 27 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
RECRUITINGBerlin, 12200, Germany
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
The START Center for Cancer Care - CIOCC
RECRUITINGMadrid, 28050, Spain
-
Universitaetsklinikum Tuebingen
RECRUITINGTübingen, 72076, Germany
-
Vall d'Hebron Institut d'Oncologia
RECRUITINGBarcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.